Pharmacyclics Triggers Another Significant Milestone Payment The FINANCIAL The FINANCIAL -- Pharmacyclics announced that the international, randomized Phase III clinical trial of ibrutinib in combination with bendamustine and rituximab in patients with relapsed or refractory chronic lymphocytic leukemia/small lymphocytic ... |
